Top

Strahlentherapie und Onkologie

Published in:

01-03-2013 | Literatur kommentiert

Primäre kurative Radiochemotherapie beim Nasopharynxkarzinom

Kumulative Cisplatin-Dosis prognostisch signifikant

Authors: Prof. Dr. H. Christiansen, PD Dr. H.A. Wolff

Published in: Strahlentherapie und Onkologie | Issue 3/2013

Auszug

Loong HH, Ma BB, Leung SF et al (2012) Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 104:300–304 …

Buehrlen M, Zwaan CM, Granzen B et al (2012) Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer 118:4892–4900PubMedCrossRef

Lau H, Brar S, Hao D et al (2006) Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: analysis of survival and toxicity. Head Neck 28:189–196PubMedCrossRef

Lee N, Harris J, Garden AS et al (2009) Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 27:3684–3690PubMedCrossRef

Mertens R, Granzen B, Lassay L et al (2005) Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH). Cancer 104:1083–1089PubMedCrossRef

Pignon JP, le Maître A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17.346 patients. Radiother Oncol 92:4–14PubMedCrossRef

Rades D, Fehlauer F, Sheikh-Sarraf M et al (2008) Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head Neck 30:235–241PubMedCrossRef

Steinmann D, Cerny B, Karstens JH et al (2009) Chemoradiotherapy with weekly cisplatin 40 mg/m² in 103 head and neck cancer patients: a cumulative dose-effect analysis. Strahlenther Onkol 185:682–688PubMedCrossRef

Wolff HA, Overbeck T, Roedel RM et al (2009) Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. J Cancer Res Clin Oncol 135:961–967PubMedCrossRef

10.

Wolff HA, Rödel RM, Gunawan B et al (2010) Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas. J Cancer Res Clin Oncol 136:89–97PubMedCrossRef

Title: Primäre kurative Radiochemotherapie beim Nasopharynxkarzinom
Kumulative Cisplatin-Dosis prognostisch signifikant
Authors: Prof. Dr. H. Christiansen
PD Dr. H.A. Wolff
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Strahlentherapie und Onkologie / Issue 3/2013
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0285-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Primäre kurative Radiochemotherapie beim Nasopharynxkarzinom

Kumulative Cisplatin-Dosis prognostisch signifikant

Auszug

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 3/2013

Professor Manfred Strietzel zum 85. Geburtstag

Prof. Dr. Hans-Joachim Thiel zum 65. Geburtstag und zur Würdigung seiner berufspolitischen Tätigkeit

Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients

Cyclin D1, EGFR, and Akt/mTOR pathway

In vitro hypoxic cytotoxicity and hypoxic radiosensitization

Erratum to: Should hyperthermia be included in the benefit catalogue for oncologic indications? Commercial interests are presumed behind the editorial of R. Sauer et al.